MarketPeel
Insider Trading Intelligence
Pricing
…
SK

Sheldon L. Koenig

ESPR
PRESIDENT AND CEO · ESPERION THERAPEUTICS, INC. · CIK 0001766524
FILING MIX · LIFETIME57%/43%
BUYS
17
SELLS
13
TOTAL VALUE
$769.3K
COMPANIES
1
ACTIVE SINCE
Jan 2021
HOLDINGS NOW
2,119,111
AVG SELL PX
$2.81
TRADE KIND
SHOWING 30 / 30
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
14 backtested trades · 8 horizons · 11 pending
Forward-return performance of every backtestable P/S trade by Sheldon L. Koenig, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d14+64.29%+0.46%+0.88%-0.42%-1.57%—
14d14+64.29%-4.75%+0.85%-5.59%-4.41%—
30d14+50.00%-5.50%+1.21%-6.71%-3.03%—
60d14+50.00%+2.85%+3.65%-0.80%+3.58%—
90d14+57.14%+9.57%+3.33%+6.25%+3.68%—
180d14(1 pending)+61.54%+7.09%+6.35%+0.74%-14.86%—
1y14(3 pending)+45.45%+6.95%+18.35%-11.41%+0.93%—
2y14(7 pending)+71.43%-50.82%+41.23%-92.05%-94.36%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ESPR · 2,119,111 shares · as of Jun 17, 2026
0549,5691,099,1391,648,7082,198,27720222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 17 buys / 13 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ESPR
ESPERION THERAPEUTICS, INC.
SALE
President and CEO
53,588$3.16$169.1K2,119,111Jun 17, 2026Jun 18, 2026 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
President and CEO
25,578$2.72$69.5K2,172,699Mar 17, 2026Mar 18, 2026 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
647,460——647,460Mar 13, 2026Mar 16, 2026 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
723,760——2,198,277Mar 13, 2026Mar 16, 2026 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
President and CEO
48,244$3.67$177.2K1,470,587Dec 17, 2025Dec 18, 2025 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
President and CEO
28,427$2.79$79.3K1,518,831Sep 17, 2025Sep 18, 2025 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
President and CEO
30,474$1.11$33.8K1,541,488Jun 17, 2025Jun 18, 2025 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
President and CEO
13,047$1.50$19.6K1,571,962Mar 18, 2025Mar 19, 2025 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
753,000——753,000Mar 14, 2025Mar 17, 2025 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
840,000——1,585,009Mar 14, 2025Mar 17, 2025 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
President and CEO
12,447$2.47$30.7K739,819Dec 17, 2024Dec 18, 2024 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
President and CEO
14,550$1.80$26.1K752,266Sep 17, 2024Sep 18, 2024 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
454,000——766,816Mar 14, 2024Mar 15, 2024 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
642,000——642,000Mar 14, 2024Mar 15, 2024 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASE
President and CEO
20,000$1.26$25.2K312,816May 9, 2023May 10, 2023 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
President and CEO
6,999$1.78$12.5K292,816Mar 17, 2023Mar 20, 2023 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
105,000——299,815Mar 14, 2023Mar 15, 2023 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
445,000——445,000Mar 14, 2023Mar 15, 2023 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
President and CEO
5,441$5.06$27.5K194,815Mar 7, 2023Mar 8, 2023 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
President and CEO
3,394$6.94$23.5K198,257Sep 19, 2022Sep 20, 2022 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASE
President and CEO
8,606$5.80$50.0K198,771Aug 5, 2022Aug 8, 2022 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
President and CEO
4,552$4.99$22.7K190,165Jun 17, 2022Jun 21, 2022 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
91,000——91,000Jun 7, 2022Jun 9, 2022 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
SALE
President and CEO
571$4.58$2.6K194,717Mar 17, 2022Mar 18, 2022 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
116,000——195,288Mar 14, 2022Mar 16, 2022 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
26,700——76,700Oct 29, 2021Nov 1, 2021 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,000——50,000May 17, 2021May 18, 2021 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
120,000——120,000May 17, 2021May 18, 2021 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
150,000——150,000Jan 28, 2021Jan 29, 2021 ↗View →
ESPR
ESPERION THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
30,000——30,000Jan 28, 2021Jan 29, 2021 ↗View →
Other insiders · ESPR
Loading peer insiders…
About this filer
CIK 0001766524
ROLE
President and CEO
PRIMARY
ESPR
COMPANIES
1
ACTIVE SINCE
Jan 2021
MARKETPEEL · /INSIDER/0001766524DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback